Global In Vitro Diagnostics Partnership Agreements Analysis Report 2010-2022: Agreements tend to be multi-component, starting with collaborative R&D and commercialization of results – ResearchAndMarkets.com

[ad_1]

DUBLIN–(BUSINESS WIRE)–The report “Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2022” has been added to from ResearchAndMarkets.com offer.

The Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2022 report provides comprehensive access to available agreements and contractual documents for over 850 in vitro diagnostic agreements.

These agreements tend to be multi-component, starting with collaborative R&D and commercialization of the results.

This report details the latest in vitro diagnostics deals announced in the life sciences since 2010.

The report presents the reader with a comprehensive review of In Vitro Diagnostics deal trends, major players, key deal values, as well as deal financials, to understand how, why, and on what terms companies are entering into deals. partnership with In Vitro Diagnostics.

The report presents the values ​​of financial transaction terms for in vitro diagnostics transactions, listed by aggregate value, upfront payments, milestone payments and royalties, allowing readers to analyze and compare the financial value of transactions.

The central section of the report explores key negotiators in the field of in vitro diagnostics partnerships; both the top deal stocks and the most active in vitro diagnostics trading companies are reported, allowing the reader to see who is succeeding in this dynamic deal market.

One of the main highlights of the report is that over 850 online records of actual in vitro diagnostic agreements, as disclosed by the parties to the agreement, are included near the end of the report in a directory format – by AZ company, stage of development, type of transaction, therapeutic focus and type of technology – easy to browse. Each transaction record in the report is linked via Weblink to an online version of the transaction.

In addition, when available, the records include contract documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies look for details on payment terms, the devil is in the details in terms of triggering payments – contract documents provide this information where press releases and databases do not.

The report also includes numerous tables and figures that illustrate in vitro diagnostics partnership and trading trends and activities since 2010.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of in vitro diagnostic technologies and products.

Key Benefits

The Global In Vitro Diagnostics 2010-2022 Partnership Terms and Agreements provide the reader with the following key benefits:

  • In-depth understanding of in vitro diagnostics transaction trends since 2010

  • Access to master, initial, milestone and royalty data

  • Detailed access to actual in vitro diagnostic contracts from major biopharmaceutical companies

  • Identify the most active IVD marketers since 2010

  • Overview of terms included in an In Vitro Diagnostics partnership agreement, with concrete examples

  • Understand the key terms of agreement that companies have agreed to in previous agreements

  • Undertake due diligence to assess the suitability of the terms of the agreement you propose for business partners

In Vitro Diagnostics partnership terms and agreements include:

  • Trends in in vitro diagnostic transactions in the biopharmaceutical industry since 2010

  • Access to master, initial, milestone and royalty data

  • Access to In Vitro Diagnostic contractual documents

  • Top IVD deals by value since 2010

  • Most active IVD negotiators since 2010

In Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2022, available offerings are listed by:

  • A-Z company

  • Face value

  • Stage of development at signing

  • Offer component type

  • Specific therapeutic target

  • Type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • What is the duration of the agreement?

  • How are the main terms of the agreement defined?

  • How are IPRs managed and owned?

  • Who is responsible for marketing?

  • Who is responsible for development, supply and manufacturing?

  • How are confidentiality and publication managed?

  • How to settle disputes?

  • Under what conditions can the agreement be terminated?

  • What happens if the owner changes?

  • What sub-licensing and sub-contracting arrangements have been agreed upon?

  • What boilerplate clauses does the company insist on?

  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

  • What jurisdiction does the company insist on for contract law?

Main topics covered:

Summary

Chapter 1 Introduction

Chapter 2 – Trends in the negotiation of in vitro diagnostics

2.1. Introduction

2.2. In Vitro Diagnostics partnership over the years

2.3. Most Active IVD Negotiators

2.4. In vitro diagnostic partnerships by transaction type

2.5. In Vitro Diagnostic Partnerships by Therapeutic Area

2.6. Terms of Agreement for In Vitro Diagnostics Partnership

2.6.1 Key values ​​of the In Vitro Diagnostics partnership

2.6.2 In Vitro Diagnostics processes initial payments

2.6.3 In Vitro Diagnostics Agreement Milestone Payments

2.6.4 Royalty rates for in vitro diagnostics

Chapter 3 – Major In Vitro Diagnostics Offerings

3.1. Introduction

3.2. Best In Vitro Diagnostics Deals by Value

Chapter 4 – Most Active IVD Negotiators

4.1. Introduction

4.2. Most Active IVD Negotiators

4.3. Profiles of the most active partner companies in the field of in vitro diagnostics

Chapter 5 – In Vitro Diagnostic Contracts Dealmaking Directory

5.1. Introduction

5.2. In Vitro Diagnostics Contracts Dealmaking Directory

Chapter 6 – In Vitro Diagnostics Transactions by Technology Type

Appendices

Appendix 1 – In Vitro Diagnostics offers by AZ company

Annex 2 – In Vitro Diagnostics offers by stage of development

Annex 3 – In vitro diagnostic transactions by type of transaction

Annex 4 – In vitro diagnostics offers by therapeutic area

Annex 5 – Definitions of transaction types

Annex 6 – Further reading on dealmaking

Companies cited

  • HelixBind

  • WuXi Organic Products

  • Aytu BioPharma

  • Roka Biosciences

  • Zora Biosciences

  • Mesa Biotech

  • Sensible medical innovations

  • MyLabBox

  • Sunnybrook Health Sciences Center

  • Unilabs

  • AmpTec

  • Glytec

  • Nordic Biolabs

  • Public Health England

  • US Providers of Choice Network

  • Clinical genomics

  • Clinical reference laboratory

  • LifeScan

  • American Medical Depot

  • American Pathology Partners

  • MagnaCare

  • lucent

  • Advanced Biology Laboratories

  • Advanced Cooling Therapy

  • Advanced Dermatology and Cosmetic Surgery Group

  • Massachusetts General Hospital

  • Massachusetts Institute of Technology

  • Massachusetts Life Science Center

  • Awareness

  • Mayo Clinic

  • Enzo Clinical Laboratories

  • MicroCoat Biotechnology

  • BioTecon Diagnostics

  • AliveCor

  • Sintact Medical Systems

  • PredictImmune

  • Medical collective

  • Biomed Trivector

  • XCellCure

  • Sensosure

  • photocurable AAS

  • PAVmed

  • Eckerd College

  • Oxford Immunotec

  • UNICEF

  • United States Agency for International Development

For more information about this report visit https://www.researchandmarkets.com/r/3ejmdq

[ad_2]
Source link

Comments are closed.